Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30600932 | 1.00 | MAPK1 (0.33) | MAPK1NPC1HSP90AA1L3MBTL1 | |
| SCHEMBL21298439 | 0.77 | CCR1 (0.43) | NPC1HSP90AA1L3MBTL1 | |
| SCHEMBL3147594 | 0.74 | HSP90AA1 (0.45) | NPC1HSP90AA1L3MBTL1 | |
| SCHEMBL203305 | 0.71 | DYRK1A (0.41) | — | |
| SCHEMBL3395413 | 0.69 | HSP90AA1 (0.45) | NPC1HSP90AA1L3MBTL1 | |
| SCHEMBL14829208 | 0.69 | NQO2 (0.32) | — | |
| SCHEMBL14829196 | 0.69 | POLB (0.31) | — | |
| SCHEMBL3142470 | 0.69 | ERN1 (0.32) | MAPK1 | |
| SCHEMBL4149779 | 0.67 | CCR1 (0.64) | NPC1HSP90AA1L3MBTL1 | |
| SCHEMBL20699181 | 0.67 | MAPK1 (0.38) | MAPK1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024411-A | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-110709392-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-3601259-B1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | HOFFMANN LA ROCHE (CH) | 2022-02-23 | — | — | EP | disclosed |
| US-20210163417-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| EP-3601259-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | H. Hoffnabb-La Roche Ag (CH) | 2020-02-05 | — | — | EP | disclosed |
| CN-110709392-A | Isoquinoline as HPK1 inhibitors | 豪夫迈·罗氏有限公司 | 2020-01-17 | — | — | CN | disclosed |
| US-20180282282-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | US | disclosed |
| WO-2018183964-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| EP-2365809-B1 | PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMA INC (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20140364423-A1 | Pyrazinopyrazines and Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. | 2014-12-11 | — | — | US | disclosed |
| US-8846664-B2 | Pyrazinopyrazines and derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846664-B2 | Pyrazinopyrazines and derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846664-B2 | Pyrazinopyrazines and derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20110288078-A1 | PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288078-A1 | PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288078-A1 | PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| EP-2233493-A1 | Macrolides | Pfizer Products Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010056311-A1 | PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-1836211-B1 | MACROLIDES | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364423-A1 | Pyrazinopyrazines and Derivatives as Kinase Inhibitors | MAP3K5, MAP3K15, MAP4K2 | MAPK1 38/4885NPC1 4413/4885HSP90AA1 2240/4885 |
| US-20180282282-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | HIPK1, HPGDS, IP6K1 | MAPK1 516/4885NPC1 931/4885HSP90AA1 680/4885 |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | HIPK1, HIPK2, IP6K1 | MAPK1 546/4885NPC1 1022/4885HSP90AA1 642/4885 |
| US-20210163417-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | HIPK1, HIPK2, IP6K1 | MAPK1 546/4885NPC1 1022/4885HSP90AA1 642/4885 |
| US-20110288078-A1 | PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | MAPK1 38/4885NPC1 4413/4885HSP90AA1 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.